Potential treatment strategy for NASH
- PMID: 30664675
- DOI: 10.1038/s41574-019-0162-1
Potential treatment strategy for NASH
Comment on
-
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.Lancet. 2019 Dec 22;392(10165):2705-2717. doi: 10.1016/S0140-6736(18)31785-9. Epub 2018 Dec 13. Lancet. 2019. PMID: 30554783 Clinical Trial.
References
Original article
-
- Sanyal, A. et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet https://doi.org/10.1016/S0140-6736(18)31785-9 (2018) - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
